TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7859638

Group type: EXPERIMENTAL
Intervention: HLA-DRw9 phenotype and HLA-Bw61/DRw9 haplotype
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: HLA-DR4 phenotype and Bw54/DR4 haplotype
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: DR4 phenotype
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: HLA-DRw9/DR4 genotype
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Gm phenotype of g and gft
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: BF-F phenotype
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: ICA prevalence
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Autoantibodies prevalence
Number of subjects: 159
Study: 2684134

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural treatment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Standard behavioural treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Routine outpatient management (Control)
Number of subjects: 24
Study: 30412514

Group type: EXPERIMENTAL
Intervention: Anodal stimulation (20 minutes, 1.5 mA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cathodal stimulation (20 minutes, 1.5 mA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham stimulation (20 minutes, 1.5 mA)
Number of subjects: 24
Study: 31973579

Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC) for 1 hour on Day 3
Number of subjects: 51
Study: 30385281

Group type: EXPERIMENTAL
Intervention: VX-985 with sodium taurocholate >4 mM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VX-985 with vitamin E D‐alpha‐tocopherol polyethylene glycol 1000 succinate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro characterization with surfactants
Number of subjects: 0
Study: 29068592

Group type: EXPERIMENTAL
Intervention: Crocin (30 mg per day for 8 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: COMPARATOR
Intervention: Comparison between Crocin and Placebo
Number of subjects: 34
Study: 25624430

Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg daily) and Letrozole (2.5 mg daily)
Number of subjects: 38
Study: 24312709

Group type: EXPERIMENTAL
Intervention: Clear Liquid Diet (CLD)
Number of subjects: 801

Group type: COMPARATOR
Intervention: Regular Diet (RD)
Number of subjects: 801
Study: 20622160

Group type: EXPERIMENTAL
Intervention: HbA(1c) diagnostic criteria
Number of subjects: 5735

Group type: EXPERIMENTAL
Intervention: Baseline HbA(1c) of 6.0-6.4%
Number of subjects: 5735

Group type: EXPERIMENTAL
Intervention: Previously undiagnosed diabetes
Number of subjects: 5735

Group type: EXPERIMENTAL
Intervention: Overall prevalence of diabetes
Number of subjects: 5735
Study: 19366302

Group type: EXPERIMENTAL
Intervention: Insulin detemir (Levemir)
Number of subjects: 0

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 0
Study: 16873908

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Waist-to-Height Ratio (WHtR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Waist-to-Hip Ratio (WHR)
Number of subjects: 0
Study: 15387400

Group type: EXPERIMENTAL
Intervention: CAGE score of 4
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Recreational drug use
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Symptoms of anti-social personality disorders
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Symptoms of childhood conduct disorder
Number of subjects: 277
Study: 11524354

Group type: EXPERIMENTAL
Intervention: Clonidine added to mepivacaine (50 microg) for median and musculocutaneous nerves
Number of subjects: 58

Group type: COMPARATOR
Intervention: Plain mepivacaine 1.5% (Control group)
Number of subjects: 58
Study: 9240902

Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional lancet
Number of subjects: 100
Study: 8236402

Group type: EXPERIMENTAL
Intervention: 20 mg/kg for 30 days
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 20 mg/kg for 15 days
Number of subjects: 104

Group type: COMPARATOR
Intervention: 10 mg/kg for 30 days
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 20 mg/kg for 30 days and 20 mg/kg for 15 days
Number of subjects: 104
Study: 3122247

Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg oral dose)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cocaine (0.2 mg/kg IV injection)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diltiazem pretreatment
Number of subjects: 6
Study: 31444210

Group type: EXPERIMENTAL
Intervention: Financial incentive for breastfeeding intervention over a 6-month period
Number of subjects: 10010

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 10010

Group type: EXPERIMENTAL
Intervention: Financial incentive for breastfeeding intervention
Number of subjects: 10010
Study: 28855345

Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment (IAT) plus usual care
Number of subjects: 500

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 500
Study: 27501767

Group type: COMPARATOR
Intervention: Bevacizumab plus paclitaxel (bevacizumab 10 mg/kg on days 1 and 15 plus paclitaxel 90 mg/m² on days 1, 8, and 15 every 4 weeks)
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus capecitabine (bevacizumab 15 mg/kg on day 1 plus capecitabine 1000 mg/m² twice daily on days 1-14 every 3 weeks)
Number of subjects: 531

Group type: COMPARATOR
Intervention: Bevacizumab plus paclitaxel
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus capecitabine
Number of subjects: 531
Study: 24477043

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) combined with a protein-enriched diet facilitated through lean red meat (∼160 g cooked, 6 days/week)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control PRT (1 serving pasta or rice/day)
Number of subjects: 100
Study: 23121374

Group type: EXPERIMENTAL
Intervention: cinacalcet
Number of subjects: 3883

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3883
Study: 20418480

Group type: EXPERIMENTAL
Intervention: Red wine (RW) - 2 drinks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ethanol (EtOH) - 2 drinks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water - 1 drink
Number of subjects: 12
Study: 18697376

Group type: EXPERIMENTAL
Intervention: Diclofenac rectal suppositories (50 mg, two tablets)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo rectal suppositories (two look-alike tablets)
Number of subjects: 72
Study: 15041587

Group type: EXPERIMENTAL
Intervention: Preoperative oral dextromethorphan 30 mg
Number of subjects: 76

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 76
Study: 11735011

Group type: EXPERIMENTAL
Intervention: Oral ofloxacin 400 mg and metronidazole 500 mg
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard intravenous prophylaxis
Number of subjects: 61
Study: 9428917

Group type: COMPARATOR
Intervention: CAF (cyclophosphamide 600 mg/m2 i.v., doxorubicin 50 mg/m2 i.v., fluorouracil 600 mg/m2 i.v.)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: DES-CAF (DES 1 mg orally days 1-3, CAF on day 4)
Number of subjects: 117
Study: 8249869

Group type: EXPERIMENTAL
Intervention: Low Protein (LP) diet
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High Fat (HF) diet
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High Carbohydrate (HC) diet
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High Protein (HP) diet
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 10
Study: 3436030

Group type: EXPERIMENTAL
Intervention: F-sterilized dialysers
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: New dialysers sterilized by ethylene oxide (not F)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (5 subjects)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Skin-prick tests with F
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: RAST to F
Number of subjects: 10
Study: 30673725

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg/day) for 20 consecutive days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo for 20 consecutive days
Number of subjects: 11
Study: 29873905

Group type: EXPERIMENTAL
Intervention: Red light source
Number of subjects: 28

Group type: COMPARATOR
Intervention: Blue light source
Number of subjects: 28
Study: 26588214

Group type: EXPERIMENTAL
Intervention: Daily text message reminders
Number of subjects: 0

Group type: COMPARATOR
Intervention: No text message reminders (Control)
Number of subjects: 0
Study: 24506498

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa every 2 weeks (Q2W)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa once monthly (QM)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Comparison of Q2W and QM
Number of subjects: 355
Study: 23135654

Group type: EXPERIMENTAL
Intervention: Microcannula
Number of subjects: 95

Group type: COMPARATOR
Intervention: Hypodermic needle
Number of subjects: 95
Study: 19714379

Group type: EXPERIMENTAL
Intervention: Split-night study
Number of subjects: 400

Group type: COMPARATOR
Intervention: Dual-night study
Number of subjects: 400
Study: 16996583

Group type: EXPERIMENTAL
Intervention: Tegafur‐Uracil 225 mg/m(2)/day orally, 5 days a week and carboplatin 100 mg/m(2) IV weekly on day 1 concurrent with standard radiotherapy (Group A)
Number of subjects: 469

Group type: COMPARATOR
Intervention: Carboplatin alone concurrent with standard radiotherapy (Group B)
Number of subjects: 469
Study: 15498381

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy and embolization via the anterior branches of the bilateral internal iliac arteries
Number of subjects: 42

Group type: COMPARATOR
Intervention: Adjuvant platinum-based combination chemotherapy (control)
Number of subjects: 42
Study: 11089279

Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia
Number of subjects: 60
Study: 9030968

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CyA)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: GnRH analogue (GnRHA)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 102
Study: 8295363

Group type: EXPERIMENTAL
Intervention: PhXA34
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: PhXA41
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: PhXA34 and PhXA41 (combined)
Number of subjects: 54
Study: 3107378

Group type: EXPERIMENTAL
Intervention: Citrate as the sole anticoagulant for periods of 2 months
Number of subjects: 6

Group type: COMPARATOR
Intervention: Heparin as an anticoagulant
Number of subjects: 6
Study: 31188694

Group type: EXPERIMENTAL
Intervention: CHO (1.2 g CHO·kg body mass‐1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10
Study: 29178442

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg in fed state
Number of subjects: 106

Group type: COMPARATOR
Intervention: Osimertinib 80 mg in fasted state
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg plus osimertinib 80 mg
Number of subjects: 106

Group type: COMPARATOR
Intervention: Osimertinib 80 mg alone
Number of subjects: 106
Study: 28197932

Group type: EXPERIMENTAL
Intervention: Triptorelin 0.2 mg
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Triptorelin 0.3 mg
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Triptorelin 0.4 mg
Number of subjects: 165

Group type: COMPARATOR
Intervention: Triptorelin doses (0.2, 0.3, 0.4 mg)
Number of subjects: 165
Study: 25908010

Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy (nCT)
Number of subjects: 181

Group type: COMPARATOR
Intervention: neoadjuvant chemoradiotherapy (nCRT)
Number of subjects: 181
Study: 23890595

Group type: EXPERIMENTAL
Intervention: aripiprazole once-monthly 200mg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: aripiprazole once-monthly 300mg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: aripiprazole once-monthly 400mg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: aripiprazole once-monthly (any dose)
Number of subjects: 41
Study: 21689363

Group type: EXPERIMENTAL
Intervention: Cold Snare Polypectomy (CSP)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Hot Snare Polypectomy (HSP)
Number of subjects: 414
Study: 18047523

Group type: EXPERIMENTAL
Intervention: Adalimumab (80 mg subcutaneously at week 0, then 40 mg every other week)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Methotrexate (7.5 mg orally, increased as needed to 25 mg weekly)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 271

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 271
Study: 16416458

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 61
Study: 12892868

Group type: EXPERIMENTAL
Intervention: S-QoL questionnaire
Number of subjects: 207
Study: 10848924

Group type: EXPERIMENTAL
Intervention: Pranlukast (225 mg orally twice daily for 4 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (oral administration for 4 weeks)
Number of subjects: 32
Study: 9085967

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ondansetron 16 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8229102

Group type: EXPERIMENTAL
Intervention: Self-administered Quality-of-Life after Myocardial Infarction (QLMI) questionnaire
Number of subjects: 0
Study: 31777212

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg/d) plus NSAID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus NSAID
Number of subjects: 0
Study: 29893296

Group type: EXPERIMENTAL
Intervention: Oral terbinafine (5mg/kg/day) and topical terbinafine 1% applied twice daily for 4 weeks
Number of subjects: 500
Study: 27515978

Group type: EXPERIMENTAL
Intervention: Guselkumab IV (0.03-10 mg/kg)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Guselkumab SC (10-300 mg)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Guselkumab IV and SC
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo SC (10, 30, 100, 300 mg)
Number of subjects: 71
Study: 25102704

Group type: EXPERIMENTAL
Intervention: Group V - single-stage surgery (radical excision of the tumor with sentinel lymph node biopsy)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Group D - two-stage surgery (initial diagnostic excision followed by radical re-excision and sentinel lymph node biopsy)
Number of subjects: 100
Study: 23281755

Group type: EXPERIMENTAL
Intervention: High energy diet
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Commercial diet
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Low energy diet
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Restricted high energy feed
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: High energy feed ad libitum
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Chickens slaughtered at 2000 g
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Chickens slaughtered at 1500 g
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Male broilers
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Female broilers
Number of subjects: 196
Study: 20624670

Group type: EXPERIMENTAL
Intervention: Fagerström Test for Nicotine Dependence (FTND)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Revised Fagerström Test for Nicotine Dependence (FTND)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Hooked on Nicotine Checklist (HONC)
Number of subjects: 73
Study: 18390635

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for 6 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 16199251

Group type: EXPERIMENTAL
Intervention: Cefdinir (once daily n = 569 or twice daily n = 1086) for 5 or 10 days
Number of subjects: 2751

Group type: COMPARATOR
Intervention: Penicillin (4 times daily n = 1096) for 10 days
Number of subjects: 2751
Study: 12451319

Group type: EXPERIMENTAL
Intervention: Pravastatin (10 or 20 mg/d)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normolipidemic control group
Number of subjects: 50
Study: 10514023

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/day
Number of subjects: 19185

Group type: COMPARATOR
Intervention: Aspirin 325 mg/day
Number of subjects: 19185
Study: 7476741

Group type: EXPERIMENTAL
Intervention: 150 ml of plain water two and half hours before surgery (Group 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (Group 2) - continued overnight fast
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (Group 3) - non-pregnant patients continued overnight fast
Number of subjects: 40
Study: 2014108

Group type: EXPERIMENTAL
Intervention: Apraclonidine 1%
Number of subjects: 260

Group type: COMPARATOR
Intervention: Acetazolamide 250 mg
Number of subjects: 260

Group type: COMPARATOR
Intervention: Dipivefrin 0.1%
Number of subjects: 260

Group type: COMPARATOR
Intervention: Pilocarpine hydrochloride 4%
Number of subjects: 260

Group type: COMPARATOR
Intervention: Timolol maleate 0.5%
Number of subjects: 260
Study: 7255001

Group type: EXPERIMENTAL
Intervention: Brazelton Neonatal Behavioral Assessment Scale and Mother's Assessment of the Behavior of Her Infant Scale (MABI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no observation of Brazelton scale, completed questionnaire on developmental milestones)
Number of subjects: 30
Study: 30684794

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 49

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 49
Study: 28836341

Group type: EXPERIMENTAL
Intervention: Sucrose-formulated recombinant FVIII prophylaxis
Number of subjects: 84

Group type: COMPARATOR
Intervention: On-demand therapy (OD)
Number of subjects: 84
Study: 25499095

Group type: EXPERIMENTAL
Intervention: Caltrate 600 mg elemental calcium; 125 IU vitamin D3, 1 tablet/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caltrate 600 mg elemental calcium; 125 IU vitamin D3, 2 tablets/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23611386

Group type: EXPERIMENTAL
Intervention: Self-adjusting file (SAF) instrumentation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ProFile instrumentation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: K-file instrumentation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 36
Study: 22416402

Group type: COMPARATOR
Intervention: Ringer solution and 10% glucose solution (1:1 ratio)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Sterofundin-G-5
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Remaksol (800 ml/day)
Number of subjects: 139
Study: 19827183

Group type: EXPERIMENTAL
Intervention: Universal competence-standards set by the experimenter
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Self-generated standards by participants
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control conditions (no scores given)
Number of subjects: 240
Study: 17368247

Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 59

Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 59
Study: 15196263

Group type: EXPERIMENTAL
Intervention: Oral administration of p336‐351 linked to cholera toxin B subunit (CTB), 3 times weekly, followed by gradual withdrawal of immunosuppressive drugs.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral administration of p336‐351 linked to cholera toxin B subunit (CTB)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Patients with relapsed uveitis
Number of subjects: 8
Study: 11476424

Group type: EXPERIMENTAL
Intervention: Eccentric overload training (12-week treatment protocol)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no eccentric overload training)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Eccentric overload training (6-week evaluation)
Number of subjects: 40
Study: 9129517

Group type: COMPARATOR
Intervention: Unweighted prosthetic limb
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Prosthetic limb with 0.68 kg added mass
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Prosthetic limb with 1.34 kg added mass
Number of subjects: 8
Study: 8164118

Group type: EXPERIMENTAL
Intervention: ePTFE + DFDBA
Number of subjects: 6

Group type: COMPARATOR
Intervention: ePTFE alone
Number of subjects: 6
Study: 3171265

Group type: EXPERIMENTAL
Intervention: Medical vagotomy (0.5 mg of atropine and 50 mg of hexamethonium bromide, injected three times at two hour intervals intramuscularly)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Medical vagotomy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no medical vagotomy)
Number of subjects: 28
Study: 29664979

Group type: COMPARATOR
Intervention: Standard ILM Peel (SIP)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Inverted ILM Flap Technique (IFT)
Number of subjects: 100
Study: 28974247

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 218

Group type: COMPARATOR
Intervention: Superficial acupuncture
Number of subjects: 218
Study: 26296394

Group type: EXPERIMENTAL
Intervention: Ultrasound results sent to the referring physician
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ultrasound results not sent to the referring physician
Number of subjects: 120
Study: 23211358

Group type: COMPARATOR
Intervention: No CAD
Number of subjects: 16451

Group type: EXPERIMENTAL
Intervention: Nonobstructive CAD
Number of subjects: 16451

Group type: EXPERIMENTAL
Intervention: Obstructive CAD (≥50% stenosis)
Number of subjects: 16451

Group type: EXPERIMENTAL
Intervention: Obstructive CAD among Caucasians
Number of subjects: 16451

Group type: EXPERIMENTAL
Intervention: Obstructive CAD among Africans
Number of subjects: 16451

Group type: EXPERIMENTAL
Intervention: Obstructive CAD among East Asians
Number of subjects: 16451

Group type: COMPARATOR
Intervention: East Asians compared to other ethnicities
Number of subjects: 16451
Study: 21601833

Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg once a day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 18301342

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 69
Study: 16525222

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillators (ICDs) for secondary prevention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacologic therapy
Number of subjects: 0
Study: 14756233

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) exposure at 2.5 atmospheres absolute for 90 min
Number of subjects: 40